Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 193-197

  Smith, V ^a   Van Praet, J T ^a   Vandooren, B ^a   Van Der Cruyssen, B ^a   Naeyaert, J M ^a   Decuman, S ^a   Elewaut, D ^a   De Keyser, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; COLLAGEN; METHYLPREDNISOLONE; RIFAMPICIN; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MYOFIBROBLAST; NAUSEA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCORING SYSTEM; SHORT FORM 36; SKIN FIBROBLAST; SKIN SCLEROSIS SCORE; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73449095775     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.095463     Document Type: Article

References (14)

1. Sakkas LI, Chikanza IC, D Platsoucas C. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:679-85.
2. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
3. Lafyatis R, Kissin E, Viger K, et al. Rituximab treatment for patients with diffuse cutaneous systemic sclerosis - a phase I study. Arthritis Rheum 2006;54:S523-4.
4. Lombardi S, Quartuccio L, Franzolini N, et al. Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis. Arthritis Rheum 2008;58:S822-3.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
7. Rannou F, Poiraudeau S, Berezne A, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), systemic sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57:94-102.
8. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006;54:3655-60.
9. Fitzmaurice GM, Laird NM, Ware JW. Applied longitudinal analysis. Hoboken: John Wiley and Sons, Inc, 2004.
10. Teng YKO, Levarht EWN, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-18.
11. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-19.
12. DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
13. Gazi H, Pope JE, Clements P, et al. Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol 2007;34:501-9.
14. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis - a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.